中國同輻(01763.HK)年度歸母淨利增16.64%至3.92億元 末期息44.07分
格隆匯3月31日丨中國同輻(01763.HK)公佈,截至2022年12月31日止年度,我們持續加大市場開拓力度,經濟效益實現較快增長。全年實現營業收入人民幣61.46億元,同比增長19.49%;淨利潤人民幣7.55億元,同比增長12.11%;歸母淨利潤人民幣3.92億元,同比增長16.64%。擬派末期息每股人民幣44.07分。
報吿期內,集團藥品實現營業收入人民幣39.23億元,同比增長4.5%。其中:顯像診斷及治療用放射性藥物方面實現收入人民幣14.59億元,同比2021年上升0.4%;呼氣檢測方面實現收入人民幣23.47億元,同比上升9.0%。
報吿期內,集團放射源產品實現營業收入人民幣5.81億元,同比增長11.7%。報吿期內,集團輻照相關業務全年營業收入實現人民幣1.65億元,同比增長14.3%。報吿期內,集團放射治療設備及相關服務全年營業收入實現人民幣7.32億元,同比增長87.7%。報吿期內,集團貿易服務及其他業務實現收入為人民幣7.45億元,同比增長121.7%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.